文献速递冠心病瓣膜病与结构性心脏病

表观酶DOT1L调控血管平滑肌细胞与单核细胞串话并经NF-κB通路抗动脉粥样硬化

The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell-monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究在体外以血小板衍生生长因子BB亚型刺激血管平滑肌细胞(VSMC)筛选早期上调的表观遗传因子,鉴定出DOT1L,并在小鼠与人动脉粥样硬化病变中观察到其定位于VSMC区域。通过VSMC特异性诱导性基因敲除小鼠与ApoE-/-高脂饮食模型交配,发现失活Dot1l显著减缓疾病进展;DOT1L及其诱导的H3K79me2标记直接调控Nf-κB-1和-2转录,进而诱导CCL5与CXCL10表达。研究还发现DOT1L基因特定多态性与冠状动脉疾病相关并伴mRNA表达升高。

要点

  • DOT1L在VSMC中经PDGF-BB刺激早期上调,并定位于小鼠和人动脉粥样硬化病变的VSMC区域
  • VSMC特异性敲除Dot1l可显著减缓ApoE-/-高脂饮食小鼠动脉粥样硬化进展
  • DOT1L经H3K79me2直接调控Nf-κB-1/-2转录并诱导CCL5、CXCL10,成为潜在治疗靶点

核心结论

  • DOT1L在VSMC基因表达的表观遗传调控中起关键作用,促进动脉粥样硬化发展,被视为血管疾病的潜在治疗靶点。

研究设计与样本

  • 体外以血小板衍生生长因子BB亚型刺激VSMC进行基因表达筛选;小鼠与人动脉粥样硬化病变评估Dot1l表达定位。
  • 采用VSMC特异性诱导性基因敲除小鼠与ApoE-/-高脂饮食动脉粥样硬化模型交配评估Dot1l对疾病进展的作用。
  • 结合RNA测序与H3K79me2染色质免疫沉淀测序解析下游机制,并分析DOT1L基因变异与冠状动脉疾病的关联。

主要发现

  • PDGF-BB刺激VSMC后Dot1l为早期上调的表观遗传因子,病变中Dot1l表达特异定位于VSMC区域。
  • VSMC中Dot1l失活显著减缓动脉粥样硬化疾病进展。
  • DOT1L及其诱导的H3K79me2标记直接调控Nf-κB-1和-2转录,进而诱导CCL5与CXCL10表达。
  • DOT1L基因特定多态性与冠状动脉疾病相关,且与mRNA表达升高相关。

临床怎么用

  • 提示DOT1L–H3K79me2–NF-κB–CCL5/CXCL10轴可作为VSMC表观调控靶点,用于动脉粥样硬化治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Histone H3 dimethylation at lysine 79 is a key epigenetic mark uniquely induced by methyltransferase disruptor of telomeric silencing 1-like (DOT1L). We aimed to determine whether DOT1L modulates vascular smooth muscle cell (VSMC) phenotype and how it might affect atherosclerosis in vitro and in vivo, unravelling the related mechanism. METHODS AND RESULTS: Gene expression screening of VSMCs stimulated with the BB isoform of platelet-derived growth factor led us to identify Dot1l as an early up-regulated epigenetic factor. Mouse and human atherosclerotic lesions were assessed for Dot1l expression, which resulted specifically localized in the VSMC compartment. The relevance of Dot1l to atherosclerosis pathogenesis was assessed through deletion of its gene in the VSMCs via an inducible, tissue-specific knock-out mouse model crossed with the ApoE-/- high-fat diet model of atherosclerosis. We found that the inactivation of Dot1l significantly reduced the progression of the disease. By combining RNA- and H3K79me2-chromatin immunoprecipitation-sequencing, we found that DOT1L and its induced H3K79me2 mark directly regulate the transcription of Nf-κB-1 and -2, master modulators of inflammation, which in turn induce the expression of CCL5 and CXCL10, cytokines fundamentally involved in atherosclerosis development. Finally, a correlation between coronary artery disease and genetic variations in the DOT1L gene was found because specific polymorphisms are associated with increased mRNA expression. CONCLUSION: DOT1L plays a key role in the epigenetic control of VSMC gene expression, leading to atherosclerosis development. Results identify DOT1L as a potential therapeutic target for vascular diseases.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Farina FM, Serio S, Hall IF, et al. The epigenetic enzyme DOT1L orchestrates vascular smooth muscle cell-monocyte crosstalk and protects against atherosclerosis via the NF-κB pathway. Eur Heart J. 2022. PMID: 35292818. doi:10.1093/eurheartj/ehac097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。